Radar · Life Sciences in Washington
Best Life Sciences Companies in Washington, United States
The 435 best Life Sciences companies in Washington, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Seattle Genetics.
By Riya SenguptaFinancials
435companies tracked
$12.6Bdisclosed funding
1unicorns
247have raised
FLIAR INTELLIGENCE · LIFE SCIENCES × WASHINGTON
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
164companies analysed
83%cloud-native stacks
2025funding peak (by rounds)
7unicorns
2016median founding year
353kcombined LinkedIn audience
50%of audience held by top 3
5companies hiring publicly (12 mo)
Ranked: Best Life Sciences companies in Washington
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Seattle Genetics Developer of antibody-drug conjugates for the treatment of cancer | $1.1B | 69 mo ago | Acquired | 2,404 | — | 1,675 patents Antibody‑drug conjugates and engineered linkers for targeted cancer therapeutics. | — |
| 2 | Avalyn Pharma Developer of therapies for the treatment of Idiopathic Pulmonary Fibrosis 57Funding top 14%Growth top 30%News top 30%Moat top 31% All 7 signals ▾Fundingtop 14% Growthtop 30% Newstop 30% Moattop 31% Techtop 40% Globalbottom 39% Marketbottom 36% Funding: Raised $289M across 5 rounds · 5 rounds over 11 yrs (0.5/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 57/100 | $289M | 10 mo ago | Public | 24 | — | — | — |
| 3 | Achieve Life Sciences Developer of plant-based alkaloid for treating smoking cessation 37Funding top 11%News top 42%Moat top 48%Tech top 50% All 7 signals ▾Fundingtop 11% Newstop 42% Moattop 48% Techtop 50% Globalbottom 44% Marketbottom 40% Growthbottom 34% Funding: Raised $264M across 5 rounds · 5 rounds over 6 yrs (0.8/yr) News: 9 BI events in 12 mo (of 54 tracked, 8 types) · -53% YoY rank vs industry peers · Fliar Intelligence Index 37/100 | $264M | 1 mo ago | Public | 25 25 → 40 (+60%) · sector median +27% | — | — | — |
| 4 | Umoja Biopharma Developer of cancer therapeutics | $263M | 17 mo ago | Series C | 168 | Michael Jensen Co-Founder | 132 patents Lentiviral vector production and engineered stem‑cell/immune cell therapies for oncology | — |
| 5 | Profound Bio Developer of novel therapies for the treatment of cancer | $250M | 28 mo ago | Acquired | — | Baiteng Zhao CEO | — | — |
| 6 | CytoDyn Developer of humanized monoclonal antibodies for the treatment and prevention of HIV infection 32Funding top 17%Growth top 35%Patents top 36%Innovation top 44% All 10 signals ▾Fundingtop 17% Growthtop 35% Patentstop 36% Innovationtop 44% Moatbottom 49% Globalbottom 36% Techbottom 35% Newsbottom 26% Marketbottom 25% Fin. healthbottom 24% Funding: Raised $250M across 23 rounds · 23 rounds over 17 yrs (1.4/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 32/100 | $250M | 3 mo ago | Public | 12 12 → 23 (+92%) · sector median +27% | — | 107 patents CCR5-targeted biologics for HIV, cancer, NAFLD/NASH and immune‑modulating therapies | 1 partnership |
| 7 | Cardiac Dimensions Developer of invasive cardiac implants for heart failure | $208M | 14 mo ago | Series E | 31 31 → 73 (+135%) · sector median +27% | — | 154 patents Recapturable cardiac valve repair devices and modular implant delivery systems | — |
| 8 | Truveta 🦄 Provider of healthcare data platform for learning services | $200M | 17 mo ago | Series C | 250 250 → 443 (+77%) · sector median +27% | Jay Nanduri Co-Founder & CTO | 17 patents Healthcare data de‑identification, normalization, analytics, and ontology matching platforms. | — |
| 9 | Outpace Bio Developer of T-cell therapies for cancer treatment | $200M | 23 mo ago | Series B | 48 48 → 73 (+52%) · sector median +27% | Scott Boyken Co-Founder | — | — |
| 10 | Kestra Medical Technologies Device to protect and support patients at risk of cardiovascular disorders | $196M | 22 mo ago | Public | 118 | Brian Webster CEO | — | 1 award |
| 11 | Callio Therapeutics Developer of multi-payload antibody-drug conjugates for cancer treatment | $187M | 15 mo ago | Series A | — | Jerome Kirkup Co-Founder & Chief Scientific Officer | — | — |
| 12 | OncoResponse Developer of immunotherapies for the treatment of cancer 64Funding top 20%Moat top 21%Patents top 24%Innovation top 27% All 8 signals ▾Fundingtop 20% Moattop 21% Patentstop 24% Innovationtop 27% Growthtop 28% Talentbottom 49% Globalbottom 42% Marketbottom 38% Funding: Raised $144M across 10 rounds · 10 rounds over 11 yrs (0.9/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 56 patents rank vs industry peers · Fliar Intelligence Index 64/100 | $144M | 13 mo ago | Series D | 33 | Clifford Stocks Founder & CEO | 56 patents Therapeutic antibodies targeting LILRB2 for immune checkpoint modulation in cancer. | — |
| 13 | Blaze Bioscience Biotechnology company improving cancer patient lives through Tumor Paint technology | $124M | 28 mo ago | Series D | 27 | — | 157 patents Patents concentrated in chemistry & materials | — |
| 14 | RareCyte Developer of technologies for the analysis of rare and single cells in the blood 60Funding top 24%Moat top 29%Patents top 32%Growth top 39% All 9 signals ▾Fundingtop 24% Moattop 29% Patentstop 32% Growthtop 39% Innovationtop 41% Markettop 47% Talentbottom 49% Globalbottom 40% Newsbottom 18% Funding: Raised $114M across 9 rounds · 9 rounds over 14 yrs (0.6/yr) Moat: Editorial + unicorn rating 7/10 · IP moat: 266 patents rank vs industry peers · Fliar Intelligence Index 60/100 | $114M | 12 mo ago | Series C | 54 54 → 61 (+13%) · sector median +27% | Joseph Victor President & CEO | 266 patents Advanced fluorescence microscopy and spectral imaging hardware for multiplexed cellular analysis | 1 launch |
| 15 | Perspective Therapeutics Developer of image guided targeted alpha-particle therapies for cancer treatment | $109M | 27 mo ago | Public | 116 116 → 147 (+27%) · sector median +27% | Thijs Spoor Chief Executive Officer | — | 4 job openings · 1 launch |
| 16 | Parse Biosciences Developer of RNA-sequencing solution-based transcriptome kit to analyze health data | $100M | 30 mo ago | Series C | 107 | Geoff Krummel Co-Founder | — | 1 job opening · 1 launch |
| 17 | Bonum Therapeutics Manufacturer of cytokine based drugs 45Funding top 22%Talent bottom 49%Tech bottom 45%Global bottom 43% All 5 signals ▾Fundingtop 22% Talentbottom 49% Techbottom 45% Globalbottom 43% Marketbottom 36% Funding: Raised $93.0M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 45/100 | $93M | 2 mo ago | Series B | 54 | John Mulligan Founder & CEO | — | — |
| 18 | Viome Life Sciences Provider of tests to prevent, treat, and cure chronic diseases, and cancer | $92M | 21 mo ago | Series C | 136 | Momchilo Vuyisich Co-Founder & Chief Science Officer | — | — |
| 19 | Arzeda Developer of enzyme design technology to bridge the gap by creating synthetic enzymes 80Funding top 20%Patents top 21%Innovation top 26%Growth top 28% All 11 signals ▾Fundingtop 20% Patentstop 21% Innovationtop 26% Growthtop 28% Moattop 28% Talenttop 28% Producttop 40% Markettop 45% Partnerstop 45% Globalbottom 42% Newsbottom 18% Funding: Raised $90.7M across 22 rounds · 22 rounds over 17 yrs (1.3/yr) Patents: 85 patents matched (strict assignee match) · 52 filings since 2022 vs 21 in 2017-21 rank vs industry peers · Fliar Intelligence Index 80/100 | $91M | 9 mo ago | Series B | 60 60 → 78 (+30%) · sector median +27% | David Baker Co-Founder | 85 patents Biocatalytic production and modification of stevia sweeteners and keto‑sugar derived chemicals | 1 partnership |
| 20 | Curevo Developer of vaccines for the treatment of various diseases 29Funding top 25%Talent top 41%Moat top 43%Patents top 48% All 9 signals ▾Fundingtop 25% Talenttop 41% Moattop 43% Patentstop 48% Techtop 50% Innovationbottom 45% Globalbottom 39% Marketbottom 22% Newsbottom 18% Funding: Raised $86.0M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) Talent: Analyst team rating 4/5 · 1 named leader on record rank vs industry peers · Fliar Intelligence Index 29/100 | $86M | 15 mo ago | Series B | 8 | George Simeon CEO | 3 patents Herpes zoster and combination vaccine formulations for immunogenic protection | — |
| 21 | Twin Strand Bio Developer of DNA sequencing technology to identify genomic mutations | $84M | 16 mo ago | Series B | 70 | Mike Schmitt Co-Founder | — | — |
| 22 | Tenpoint Therapeutics Developer of engineered cell-based therapeutics to restore vision 50Funding top 23%Talent top 23%Moat top 31%Growth top 33% All 8 signals ▾Fundingtop 23% Talenttop 23% Moattop 31% Growthtop 33% Techtop 49% Newstop 49% Globalbottom 39% Marketbottom 26% Funding: Raised $70.0M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) Talent: 8 named leaders on record · 8 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 50/100 | $70M | 4 mo ago | Series B | 14 | Jose Sahel Co-Founder | — | — |
| 23 | Aptevo Therapeutics Developing T-cell cytotoxicity targeted immunotherapeutic drugs primarily for cancer and hematology | $57M | 14 mo ago | Public | 45 45 → 56 (+24%) · sector median +27% | Marvin White President and CEO | — | — |
| 24 | A-Alpha Bio Developer of cell-based tool for the measurements of protein interactions | $45M | 24 mo ago | Series A | 39 39 → 49 (+26%) · sector median +27% | Randolph Lopez Co-founder & CTO | — | 1 launch · 1 award |
| 25 | Immusoft Developer of programmed B cell therapies for protein delivery | $44M | 24 mo ago | Series B | 20 | Matthew Scholz Founder | 66 patents Engineered B cells as living factories for therapeutic protein delivery and disease treatment | — |
| 26 | OtoNexus Developer of ultrasound device to non-invasively detect middle ear infections | $33M | 9 mo ago | Series C | 16 | Caitlin Cameron Co-Founder & CEO | — | — |
| 27 | Cyrus Biotechnology Developer of cloud-based protein-modelling software for drug discovery | $32M | 17 mo ago | Series B | 23 23 → 17 (-26%) · sector median +27% | — | — | — |
| 28 | HDT Bio Developer of immunotherapy for the treatment of cancer & infectious diseases | $31M | 12 mo ago | Seed | 32 32 → 54 (+69%) · sector median +27% | — | — | 1 award |
| 29 | Healionics Manufacturer of synthetic biomaterials and implantable medical devices 27Talent top 15%Moat top 25%Funding top 35%Patents top 42% All 9 signals ▾Talenttop 15% Moattop 25% Fundingtop 35% Patentstop 42% Innovationbottom 47% Globalbottom 40% Techbottom 32% Marketbottom 20% Newsbottom 18% Talent: Analyst team rating 5/5 Moat: Editorial + unicorn rating 7/10 · IP moat: 42 patents rank vs industry peers · Fliar Intelligence Index 27/100 | $27M | 6 mo ago | Series C | 10 | — | 42 patents Implantable vascular grafts and porous ocular drug‑delivery devices for eye disease treatment | — |
| 30 | LumiThera Developer of photobiomodulation treatments for ocular diseases | $26M | 15 mo ago | Acquired | 18 18 → 16 (-11%) · sector median +27% | James Carroll Co-Founder | 41 patents Non‑invasive multi‑wavelength phototherapy devices for ocular and tissue disease treatment. | — |
| 31 | Araceli Biosciences Developer of scientific tools for tissue and cell-based biomarker discovery & drug development | $26M | 13 mo ago | Seed | 34 | — | 49 patents Advanced fluorescence microscopy imaging and optical system optimization for improved image analysis | 1 launch |
| 32 | Oisín Biotechnologies Developer of genetically targeted intervention therapy for age-related diseases | $25M | 17 mo ago | Series A | 18 | Gary Hudson Co-Founder & Chairman | — | — |
| 33 | Virtici Transforms innovations into life-changing medical products through leadership, space, and funding 11Funding top 42%Global bottom 35%Patents bottom 29%Innovation bottom 19% All 4 signals ▾Fundingtop 42% Globalbottom 35% Patentsbottom 29% Innovationbottom 19% Funding: Raised $24.2M across 27 rounds · 27 rounds over 14 yrs (1.9/yr) Global: Single-market focus (United States) rank vs industry peers · Fliar Intelligence Index 11/100 | $24M | 10 mo ago | Funding Raised | 9 | — | 7 patents Inducing immune tolerance to peptide antigens for allergy and immune activation therapies | — |
| 34 | PAI Life Sciences Translational research for neglected diseases, vaccines, adjuvants, and protein biotherapeutics | $24M | 13 mo ago | Funding Raised | 5 | — | — | — |
| 35 | Curi Bio Manufacturer of drugs for multiple therapautic areas 60Funding top 25%Growth top 28%Tech top 33%Talent bottom 49% All 8 signals ▾Fundingtop 25% Growthtop 28% Techtop 33% Talentbottom 49% Newsbottom 42% Marketbottom 40% Moatbottom 38% Globalbottom 37% Funding: Raised $21.0M across 13 rounds · 13 rounds over 5 yrs (2.6/yr) Growth: Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 60/100 | $21M | 6 mo ago | Series B | 47 47 → 57 (+21%) · sector median +27% | Nicholas Geisse CEO | — | — |
| 36 | Archon Bio Provider of computational platform to develop protein therapeutics | $20M | 19 mo ago | Seed | — | George Ueda Co-Founder & CTO | — | — |
| 37 | Talus Provider of drug discovery platform for gene regulators | $20M | 14 mo ago | Seed | 15 | Alex Federation Co-Founder & CEO | 27 patents Automotive interior storage and organization systems for floor and cargo compartments | — |
| 38 | InBios Innovating immunodiagnostics for infectious diseases, improving global health outcomes | $18M | 13 mo ago | Funding Raised | 73 | Estela Raychaudhuri CEO & President | 24 patents Rapid lateral flow immunoassays for detecting viral and parasitic infectious diseases | — |
| 39 | Orlance Developer of a platform to deliver nucleic acid vaccines and related therapies | $14M | 14 mo ago | Funding Raised | — | Kristyn Aalto CEO | 5 patents Needle‑free drug/medical delivery devices and injection technologies. | — |
| 40 | Accipiter Biosciences Developer of de novo protein therapies for complex diseases treatment | $13M | 7 mo ago | Seed | — | Javier Castellanos Co-Founder & CTO | — | — |
| 41 | Cancer Targeted Technology Developing targeted small molecule drugs for cancer diagnosis and treatment | $10M | 21 mo ago | Funding Raised | 4 | — | 90 patents PSMA-targeted small-molecule drug conjugates for cancer imaging and therapy | — |
| 42 | Synthesize Bio Provider of AI-generated gene expression data for biological research purposes | $10M | 9 mo ago | Series A | — | Robert Bradley Co-Founder | — | 1 launch · 1 award |
| 43 | Orthocare Innovations Developer of prosthetics and orthotics for disability patients | $6M | 14 mo ago | Series A | 9 | — | 58 patents Patents concentrated in health & consumer products | — |
| 44 | Phase Genomics Provider of laboratory and computational services and products | $6M | 13 mo ago | Series A | 19 19 → 14 (-26%) · sector median +27% | — | 22 patents High-throughput sequencing-based genome analysis and bacterial lysin therapeutics. | 1 launch |
| 45 | VerAvanti Innovating intravascular imaging with advanced single-use endoscopes for enhanced patient care 29Growth top 35%Moat top 38%Funding top 41%Product top 46% All 10 signals ▾Growthtop 35% Moattop 38% Fundingtop 41% Producttop 46% Techbottom 48% Patentsbottom 48% Innovationbottom 44% Globalbottom 31% Marketbottom 22% Newsbottom 22% Growth: Fresh capital in last 24 mo Moat: Editorial + unicorn rating 5/10 · IP moat: 8 patents rank vs industry peers · Fliar Intelligence Index 29/100 | $6M | 7 mo ago | Series B | 13 | — | 8 patents Integrated optical coherence tomography and RGB imaging for real-time medical diagnostics | 1 launch · 1 award |
| 46 | Potato Developer of an AI platform for life science research execution | $6M | 14 mo ago | Series A | — | Ryan Kosai Co-Founder & CTO | — | — |
| 47 | PETX Optimizing breast cancer therapy with advanced imaging technology | $5M | 15 mo ago | Funding Raised | 5 | Paul E. Kinahan Co-Founder | — | — |
| 48 | PharmaIN Biopharmaceutical company pioneering subcutaneous therapies for liver disease and cancer | $2M | 10 mo ago | Seed | 17 | — | 142 patents Targeted peptide delivery using cationic lipids and NPRA/V1A receptor agonists | 1 job opening |
| 49 | Inmedix Developer of the device for diagnosing auto-immune disease | $720K | 8 mo ago | Seed | 3 | — | 4 patents Portable ECG monitoring and HRV-based infectious disease diagnostic and therapeutic solutions | — |
| 50 | Precision Quantomics Developer of quantitative proteomics assays for drug development | $294K | 2 mo ago | Funding Raised | — | Bhagwat Prasad Co-Founder | — | 1 award |
Top 12 Life Sciences companies in Washington
#1
Public · Seattle, Washington · founded 1991 · 25 employees$263.6Mraised▾
Public · Seattle, Washington · founded 1991 · 25 employees
Developer of plant-based alkaloid for treating smoking cessation. The company is developing Cytisinicline, which is a plant-based alkaloid with a binding affinity to the α4β2 nicotine receptor. The candidate is expected to block nicotine cravings and reduce the severity of nicotine withdrawal symptoms.
Fliar Intelligence Index™ 37how this company ranks against its industry peers
Funding
top 11%News
top 42%Moat
top 48%Tech
top 50%Global
bottom 44%Market
bottom 40%Funding: Raised $264M across 5 rounds · 5 rounds over 6 yrs (0.8/yr) · Last round Post IPO (Apr 2026)
News: 9 BI events in 12 mo (of 54 tracked, 8 types) · -53% YoY · Top themes: Leadership, Earnings
Moat: Editorial + unicorn rating 4/10 · 9 curated direct competitors tracked
Audience (LinkedIn): 3k LinkedIn followers
Funding rounds
- Apr 2026Post IPO$180M
- Feb 2024Post IPO$60M
- Nov 2022Post IPO$18.9M
- Aug 2021Grant (prize money)$2.8M
Investors
Propel Bio Partners, Nantahala Capital Management, Sopharma Group, HHS, Frazier Life Sciences, TPG
Tech stack
Apache Http ServerBootstrapCdnjsCloudflareCloudflare Bot ManagementGoogle Tag Manager
#2
Public · Vancouver, Washington · founded 2002 · 12 employees$249.7Mraised▾
Public · Vancouver, Washington · founded 2002 · 12 employees
Developer of humanized monoclonal antibodies for the treatment and prevention of HIV infection. It offers lead candidate, PRO 140,for HIV with demonstrated antiviral activity in men. PRO 140 blocks the HIV co-receptor CCR5 on T-cells that prevent viral entry.
Fliar Intelligence Index™ 32how this company ranks against its industry peers
Funding
top 17%Growth
top 35%Patents
top 36%Innovation
top 44%Moat
bottom 49%Global
bottom 36%Funding: Raised $250M across 23 rounds · 23 rounds over 17 yrs (1.4/yr) · Last round Post IPO (Mar 2026)
Growth: Fresh capital in last 24 mo
Patents: 107 patents matched (strict assignee match) · 25 filings since 2022 vs 49 in 2017-21 · Latest publication 2025
Audience (LinkedIn): 4k LinkedIn followers
Activity (LinkedIn): 1 partnerships (incl. Natera) announced in 12 mo
Funding rounds
- Mar 2026Post IPO$17.5M
- Jan 2026Post IPO$18.6M
- Apr 2022Post IPO$1.9M
- Dec 2021Post IPO$11.4M
Investors
Cool Blue Capital, Centrecourt Asset Management, 4-Good Ventures
Tech stack
Amazon Web ServicesApache Http ServerApple Icloud MailBootstrapFancyboxGoogle Analytics
#3
Series B · Seattle, Washington · founded 2021 · 54 employees$93Mraised▾
Series B · Seattle, Washington · founded 2021 · 54 employees
Manufacturer of cytokine based drugs
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Funding
top 22%Talent
bottom 49%Tech
bottom 45%Global
bottom 43%Market
bottom 36%Funding: Raised $93.0M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) · Last round Series B (Apr 2026)
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Tech: 24 technologies across 3/8 capability areas · Cloud: Cloudflare · Security: Cloudflare Bot Management, Http/3
Audience (LinkedIn): 6k LinkedIn followers
Funding rounds
- Apr 2026Series B$26.9M
- Nov 2022Series A$93M
Founders & team
Investors
Vivo Capital, Roche, RiverVest Venture Partners, Digitalis Ventures, 3x5 Partners, Codon Capital
#4
Series B · Seattle, Washington · founded 2020 · 14 employees$70Mraised▾
Series B · Seattle, Washington · founded 2020 · 14 employees
Developer of engineered cell-based therapeutics to restore vision. The company is advancing cell-based therapies and in vivo reprogramming to restore vision loss caused by the deterioration of functional tissue for people with degenerative ocular diseases.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Funding
top 23%Talent
top 23%Moat
top 31%Growth
top 33%Tech
top 49%News
top 49%Funding: Raised $70.0M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) · Last round Series B (Jan 2026)
Talent: 8 named leaders on record · 8 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
Funding rounds
- Jan 2026Conventional Debt$150M
- Jan 2026Series B$85M
- Jul 2023Series A$70M
- 2021Seed—
Founders & team
Investors
British Patient Capital, F-Prime Capital, Sofinnova Partners, Qiming, Eight Roads Ventures, UCL Technology Fund
Tech stack
AccessibeAnime.JsCookieyesCore-JsElementorFastly
#5
Public · Seattle, Washington · founded 2011 · 24 employees$288.9Mraised▾
Public · Seattle, Washington · founded 2011 · 24 employees
Developer of therapies for the treatment of Idiopathic Pulmonary Fibrosis. The company's lead program, Aerodone inhaled pirfenidone provides GP-101, an aerosol pirfenidone formulation for direct inhalation delivery to the lungs for the treatment of IPF. FDA has granted orphan-drug designation to Genoa for the use of pirfenidone.
Fliar Intelligence Index™ 57how this company ranks against its industry peers
Funding
top 14%Growth
top 30%News
top 30%Moat
top 31%Tech
top 40%Global
bottom 39%Funding: Raised $289M across 5 rounds · 5 rounds over 11 yrs (0.5/yr) · Last round Series D (Jul 2025)
Growth: Fresh capital in last 24 mo
News: 5 BI events in 12 mo (of 12 tracked, 3 types) · +25% YoY · 5 high-value events (IPO/M&A/funding/contracts) in 12 mo
Audience (LinkedIn): 9k LinkedIn followers — 2.6% of this cohort's audience
Funding rounds
- Jul 2025Series D$100M
- Sep 2023Series C$189.2M
- Apr 2020Series B$35.5M
- 2017Series A—
Investors
F-Prime Capital, Novo Holdings, RiverVest Venture Partners, TPG, Norwest, Pivotal bioVenture Partners China
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAmazon Web Services
#6
Series B · Seattle, Washington · founded 2008 · 60 employees$90.7Mraised▾
Series B · Seattle, Washington · founded 2008 · 60 employees
Developer of enzyme design technology to bridge the gap by creating synthetic enzymes. The proprietary technology combines targeted computational enzyme design and protein optimization with metabolic bioengineering to create entirely novel designer cell factories capable of industry-scale chemical production.
Fliar Intelligence Index™ 80how this company ranks against its industry peers
Funding
top 20%Patents
top 21%Innovation
top 26%Growth
top 28%Moat
top 28%Talent
top 28%Funding: Raised $90.7M across 22 rounds · 22 rounds over 17 yrs (1.3/yr) · Last round Series B (Aug 2025)
Patents: 85 patents matched (strict assignee match) · 52 filings since 2022 vs 21 in 2017-21 · Latest publication 2026
Innovation: 85 patents (top 21% of patent-holders) · 52 filings since 2022 vs 21 in 2017-21 · 2 product lines
Audience (LinkedIn): 9k LinkedIn followers — 2.5% of this cohort's audience
Activity (LinkedIn): 3 partnerships (incl. MANE) announced in 12 mo
Funding rounds
- Aug 2025Series B$4.5M
- May 2025Grant (prize money)$1.7M
- Apr 2025Grant (prize money)$2.2M
- Oct 2023Series B$38M
Founders & team
Investors
Universal Materials Incubator, Casdin Capital, Conti Ventures, Lewis & Clark Agrifood, Circulate Capital, OS Fund
#7
Series C · Seattle, Washington · founded 2007 · 10 employees$26.6Mraised▾
Series C · Seattle, Washington · founded 2007 · 10 employees
Healionics is a manufacturer of synthetic biomaterials and implantable medical devices. It provides tissue regeneration and device bio integration solutions to medical device manufacturers. It offers sphere-templated angiogenic regeneration (STAR) technology, which provides substrate independent, precision-engineered, and 3D biomaterial scaffolds that enhance the bio-integration and promote healing of implanted medical devices. The company’s products are used in various areas, including wound care, aesthetic medicine, cardiovascular surgery, diabetes, general surgery, ophthalmology, pain management, regenerative medicine, and urological/women's health.
Fliar Intelligence Index™ 27how this company ranks against its industry peers
Talent
top 15%Moat
top 25%Funding
top 35%Patents
top 42%Innovation
bottom 47%Global
bottom 40%Talent: Analyst team rating 5/5
Moat: Editorial + unicorn rating 7/10 · IP moat: 42 patents
Funding: Raised $26.6M across 18 rounds · 18 rounds over 18 yrs (1.0/yr) · Last round Series C (Dec 2025)
Audience (LinkedIn): 724 LinkedIn followers
Funding rounds
- Dec 2025Series C$2M
- Apr 2024Grant (prize money)$953.4K
- Oct 2023Series C$5.5M
- May 2021Series C$5.5M
Investors
Keiretsu Capital, Bellingham Angel Group, Alliance of Angels, Tacoma Angel Network, ZINO Society, Keiretsu Forum
Tech stack
WordpressMysqlPhpContact Form 7Yoast SeoNginx
#8
Series E · Kirkland, Washington · founded 2001 · 31 employees$207.8Mraised▾
Series E · Kirkland, Washington · founded 2001 · 31 employees
Cardiac Dimensions is a developer of invasive cardiac implants for heart failure. The medical device company focused on treatment of heart failure and mitral regurgitation (MR). The Carillon Mitral Contour System is a non-surgical device to treat functional MR. This permanent implant is placed using a catheter-based procedure via the jugular vein to reshape the mitral valve.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 7k LinkedIn followers
Funding rounds
- Mar 2025Series E$53M
- Jan 2023Series D$35M
- Sep 2020Series C$17.5M
- Apr 2018Venture Debt$12M
Investors
Aperture Venture Partners, Arboretum Ventures, Hostplus, Life Sciences Partners, Lumira Ventures, M.H. Carnegie & Co
Tech stack
AzureCloudflareCloudflare Bot ManagementContact Form 7Google AnalyticsGoogle Font Api
#9
Series B · Seattle, Washington · founded 2015 · 47 employees$21Mraised▾
Series B · Seattle, Washington · founded 2015 · 47 employees
Manufacturer of drugs for multiple therapautic areas
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Funding
top 25%Growth
top 28%Tech
top 33%Talent
bottom 49%News
bottom 42%Market
bottom 40%Funding: Raised $21.0M across 13 rounds · 13 rounds over 5 yrs (2.6/yr) · Last round Series B (Dec 2025)
Growth: Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo
Tech: 35 technologies across 5/8 capability areas · Cloud: Amazon Web Services, Cloudflare · Observability: Microsoft Clarity
Audience (LinkedIn): 10k LinkedIn followers — 2.8% of this cohort's audience
Funding rounds
- Dec 2025Series B$10M
- Feb 2025Grant (prize money)$2.3M
- Jan 2025Grant (prize money)$2.1M
- Dec 2023Grant (prize money)$2.3M
Founders & team
Investors
UTC Investment, DS, Dynamk Capital, NIH, HHS, Cascadia Venture Forum
Tech stack
Amazon Web ServicesAngularCallrailCart FunctionalityCloudflareCloudflare Bot Management
#10
Series C · Seattle, Washington · founded 2009 · 54 employees$114.3Mraised▾
Series C · Seattle, Washington · founded 2009 · 54 employees
Developer of technologies for the analysis of rare and single cells in the blood. The company's technologies enable convenient preparation and sophisticated multiparametric phenotypic analysis of rare cells including individual rare cell capture and retrieval for genomic analysis. Its technology platform has two integrated components AccuCyte (blood separation system) and CyteFinder (an instrument for cell imaging and analysis).
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Funding
top 24%Moat
top 29%Patents
top 32%Growth
top 39%Innovation
top 41%Market
top 47%Funding: Raised $114M across 9 rounds · 9 rounds over 14 yrs (0.6/yr) · Last round Grant (prize money) (May 2025)
Moat: Editorial + unicorn rating 7/10 · IP moat: 266 patents · 10 curated direct competitors tracked
Patents: 266 patents matched (strict assignee match) · 35 filings since 2022 vs 105 in 2017-21 · Latest publication 2026
Audience (LinkedIn): 6k LinkedIn followers
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- May 2025Grant (prize money)$658.3K
- Jun 2024Series C$20M
- Jul 2023Series C$13.2M
- Sep 2021Series C$24M
Founders & team
Investors
Health Quest Capital, 5AM Ventures, Telegraph Hill Partners, F-Prime Capital, Arboretum Ventures, Agilent
#11
Series D · Seattle, Washington · founded 2015 · 33 employees$143.6Mraised▾
Series D · Seattle, Washington · founded 2015 · 33 employees
Developer of immunotherapies for the treatment of cancer. The company uses a proprietary technology platform to discover human antibodies and an immune checkpoint inhibitor (CPI). The company’s lead candidate is OR2805 for the treatment of multiple tumor types.
Fliar Intelligence Index™ 64how this company ranks against its industry peers
Funding
top 20%Moat
top 21%Patents
top 24%Innovation
top 27%Growth
top 28%Talent
bottom 49%Funding: Raised $144M across 10 rounds · 10 rounds over 11 yrs (0.9/yr) · Last round Series D (Apr 2025)
Moat: Editorial + unicorn rating 8/10 · IP moat: 56 patents · Soonicorn
Patents: 56 patents matched (strict assignee match) · 48 filings since 2022 vs 8 in 2017-21 · Latest publication 2026
Funding rounds
- Apr 2025Series D$6M
- May 2023Grant (prize money)$13M
- May 2023Series D$14M
- Feb 2022Conventional Debt$50M
Founders & team
Investors
state.tx.us, Oxford Finance, Baxalta, RiverVest Venture Partners, Qatar Investment Authority, Rice University
#12
Series C · Seattle, Washington · founded 2010 · 16 employees$32.9Mraised▾
Series C · Seattle, Washington · founded 2010 · 16 employees
Developer of an ultrasound device to non-invasively detect middle ear infections or Otitis Media in both children and adults. The doctor points the device at the eardrum, the device then sends an ultrasound signal that detects if fluid is present behind the eardrum, and if so, what type. Currently, doctors often suggest waiting for 24-48 hours to see if the problem resolves before prescribing antibiotics. According to the founder, OtoNexus's handheld doppler ultrasound will eliminate the need to wait.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 2k LinkedIn followers
Activity: 1 awards announced in 12 mo
Funding rounds
- Sep 2025Grant (prize money)$1.2M
- Oct 2022Series C$12.9M
- Dec 2021Series C$1.9M
- Apr 2021Series C—
Founders & team
Investors
Keiretsu Capital, Mindshift Capital, Keiretsu Forum, InnovateHer Seattle, FDA, Children's Hospital of Philadelphia
Funding & investor landscape
$12.6Btotal disclosed funding
260companies funded
1,346disclosed rounds
3rounds last 90 days
Most active investors
Notable founders
John Mulligan
Founder & CEO · Bonum Therapeutics
Jose Sahel
Co-Founder · Tenpoint Therapeutics
Lyndon Cruz
Co-Founder · Tenpoint Therapeutics
David Baker
Co-Founder · Arzeda
Daniela Grabs-Rothlisberger
Co-Founder · Arzeda
Nicholas Geisse
CEO · Curi Bio
Joseph Victor
President & CEO · RareCyte
Clifford Stocks
Founder & CEO · OncoResponse
Caitlin Cameron
Co-Founder & CEO · OtoNexus
Michael Jensen
Co-Founder · Umoja Biopharma
Andrew Scharenberg
Co-Founder & CEO · Umoja Biopharma
Jerome Kirkup
Co-Founder & Chief Scientific Officer · Callio Therapeutics
Prism market signals · United States · country-scoped Prism corpus, 1,465,538 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH IN WASHINGTON · Health & Bio
How research on Biotechnology in Washington is moving
A read on the academic research around Biotechnology in Washington — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 179 papers.
University of Washington and affiliates lead DNA repair, RNA splicing, and bacterial genetics research across 179 papers, with a cautiously optimistic stance (0.48) skewed toward breakthroughs over concerns.
179 papers · stance +0.48 · 49% breakthrough · 17% concern
top institutions
- University of Washington77
- Washington University in St. Louis62
- Washington State University23
- George Washington University12
- University of Washington Medical Center7
leading researchers
Joshua C. Hincks · Heather N. Currey · James Brett Case · John Sidney · Lihong V. Wang · Matvey Goldberg
prism intelligence · tone & topics
83% positive · 4% critical tone
HealthPharmaceuticalsMedical ResearchGeneticsBiologyClinical Trials
▲
Breakthroughs72 · 40%
▼ 47%→36% share
▼0.8× share momentum0 median citations60% since 2021mostly methods-led
Antibody research newly emerged with 5 papers, while Monoclonal antibody quadrupled, signaling intensifying therapeutic discovery focus.
rising sub-themes (early→recent)
- Mutation1→5
- Monoclonal antibody1→4
- RNA splicing1→3
- Gene1→3
- Transcription factor1→3
Newly emergingAntibody 0→5 · In vitro 0→3 · Antigen 0→3
Landmark Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma · 3,223 cites
◆
Advancements51 · 28%
▲ 20%→32% share
▲1.6× share momentum0 median citations76% since 2021mostly empirical
Advancements field-share surged 20%->32%; In vivo and Downregulation/upregulation research rising, reflecting maturing translational pipelines.
rising sub-themes (early→recent)
- In vivo6
- Downregulation and upregulation4
- Cell3
- Transcriptome3
- Antigen3
Newly emergingDownregulation and upregulation 0→4 · Antigen 0→3
Landmark Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fall · 1,038 cites
▼
Concerns25 · 14%
▼ 24%→9% share
▼0.4× share momentum370 median citations44% since 2021mostly reviews
Concerns cooling sharply 24%->9% field-share, though Antibiotic resistance and Biofilm each doubled, flagging persistent antimicrobial threats.
rising sub-themes (early→recent)
- Antibiotic resistance2
- Preclinical imaging2
- Biofilm2
- Mutation2
- Micronutrient2
Landmark <p>Antimicrobial Resistance: Implications and Costs</p> · 1,882 cites
Common questions
How many Life Sciences companies are there in Washington, United States?
Radar tracks 435 indexable Life Sciences companies headquartered in Washington, United States that meet our profile-completeness bar.
What is the total funding raised by Life Sciences companies in Washington, United States?
The Life Sciences companies in Washington, United States on this list have raised a combined $12.6B in disclosed equity funding across 260 funded companies.
Which is the highest-funded Life Sciences company in Washington, United States?
Seattle Genetics is the highest-funded Life Sciences company in Washington, United States, with $1.1B in disclosed equity funding.
How many Life Sciences companies in Washington, United States are funded?
260 of the 435 Life Sciences companies in Washington, United States on this list have disclosed at least one equity funding round.
How many Life Sciences unicorns are there in Washington, United States?
1 Life Sciences company in Washington, United States on this list is valued at $1B or more.
Who are the top investors in Washington, United States Life Sciences companies?
The most active investors in Washington, United States Life Sciences companies on this list include HHS, Washington Research Foundation, Alexandria, Arch Venture Partners, National Science Foundation.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.